Cargando…

Downsizing Treatment with Tyrosine Kinase Inhibitors in Patients with Advanced Gastrointestinal Stromal Tumors Improved Resectability

BACKGROUND: Gastrointestinal stromal tumors (GISTs) express the receptor tyrosine kinase KIT. Most GISTs have mutations in the KIT or PDGFRA gene, causing activation of tyrosine kinase. Imatinib, a tyrosine kinase inhibitor (TKI), is the first-line palliative treatment for advanced GISTs. Sunitinib...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sjölund, Katarina, Andersson, Anna, Nilsson, Erik, Nilsson, Ola, Ahlman, Håkan, Nilsson, Bengt
Formato:	Texto
Lenguaje:	English
Publicado:	Springer-Verlag 2010
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2917560/ https://www.ncbi.nlm.nih.gov/pubmed/20512492 http://dx.doi.org/10.1007/s00268-010-0639-5

Ejemplares similares

Adjuvant imatinib treatment improves recurrence-free survival in patients with high-risk gastrointestinal stromal tumours (GIST)
por: Nilsson, B, et al.
Publicado: (2007)

Characterizing gastrointestinal stromal tumors and evaluating neoadjuvant imatinib by sequencing of endoscopic ultrasound-biopsies
por: Hedenström, Per, et al.
Publicado: (2017)

Pretreatment Tumor DNA Sequencing of KIT and PDGFRA in Endosonography-Guided Biopsies Optimizes the Preoperative Management of Gastrointestinal Stromal Tumors
por: Hedenström, Per, et al.
Publicado: (2020)

Why tyrosine kinase inhibitor resistance is common in advanced gastrointestinal stromal tumors
por: Tomasetti, Cristian, et al.
Publicado: (2013)

The Role of Surgical Resection Following Tyrosine Kinase Inhibitors Treatment in Patients with Advanced Gastrointestinal Stromal Tumors: A Systematic Review and Meta-analysis
por: Guo, Yinghao, et al.
Publicado: (2019)

Reducing uncertainty in health-care resource allocation
por: Simonsson, T, et al.
Publicado: (2007)

Advanced gastrointestinal stromal tumor patients benefit from palliative surgery after tyrosine kinase inhibitors therapy
por: Qiu, Hai-Bo, et al.
Publicado: (2018)

Neoadjuvant, adjuvant and palliative treatment of gastrointestinal stromal tumours (GIST) with imatinib: a centre-based study of 17 patients
por: Bümming, P, et al.
Publicado: (2003)

Increased therapeutic effect on medullary thyroid cancer using a combination of radiation and tyrosine kinase inhibitors
por: Sandblom, Viktor, et al.
Publicado: (2020)

Prevalence of Germline Mutations in Patients with Pheochromocytoma or Abdominal Paraganglioma and Sporadic Presentation: A Population-Based Study in Western Sweden
por: Muth, Andreas, et al.
Publicado: (2012)

Chinese consensus on management of tyrosine kinase inhibitor-associated side effects in gastrointestinal stromal tumors
por: Li, Jian, et al.
Publicado: (2018)

Cost-Effectiveness Analysis of Tyrosine Kinase Inhibitors in Gastrointestinal Stromal Tumor: A Systematic Review
por: Feng, Mingyang, et al.
Publicado: (2022)

Clinical relevance of integrin alpha 4 in gastrointestinal stromal tumours
por: Pulkka, Olli‐Pekka, et al.
Publicado: (2018)

Selecting Tyrosine Kinase Inhibitors for Gastrointestinal Stromal Tumor with Secondary KIT Activation-Loop Domain Mutations
por: Hsueh, Yuan-Shuo, et al.
Publicado: (2013)

Downsizing information systems
por: Guengerich, Steven
Publicado: (1992)

Complete resection of recurrent and initially unresectable dermatofibrosarcoma protuberans downsized by Imatinib
por: Wicherts, Dennis A, et al.
Publicado: (2013)

Antitumor Effect of the Tyrosine Kinase Inhibitor Nilotinib on Gastrointestinal Stromal Tumor (GIST) and Imatinib-Resistant GIST Cells
por: Sako, Hiroyuki, et al.
Publicado: (2014)

Establishment and characterization of patient-derived xenograft models of gastrointestinal stromal tumor resistant to standard tyrosine kinase inhibitors
por: Na, Young-Soon, et al.
Publicado: (2017)

Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours
por: Serrano, César, et al.
Publicado: (2019)

Neoadjuvant tyrosine kinase inhibitors in rectal gastrointestinal stromal tumours: a provision for enhanced oncological and functional outcomes
por: Yong, Zachary Zihui, et al.
Publicado: (2021)

Fibrinogen‐like protein 2 in gastrointestinal stromal tumour
por: Pulkka, Olli‐Pekka, et al.
Publicado: (2022)

Correction: Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours
por: Serrano, César, et al.
Publicado: (2019)

Locally advanced cholangiolocellular carcinoma successfully treated with curative resection after downsizing chemotherapy: a case report
por: Hozaka, Yuto, et al.
Publicado: (2021)

Prognostic value of Onodera’s nutritional index for intermediate- and high-risk gastrointestinal stromal tumors treated with or without tyrosine kinase inhibitors
por: Wang, Feng, et al.
Publicado: (2021)

A Novel Receptor Tyrosine Kinase Switch Promotes Gastrointestinal Stromal Tumor Drug Resistance
por: Boichuk, Sergei, et al.
Publicado: (2017)

Oncogenic signaling by Kit tyrosine kinase occurs selectively on the Golgi apparatus in gastrointestinal stromal tumors
por: Obata, Y, et al.
Publicado: (2017)

SLUG transcription factor: a pro-survival and prognostic factor in gastrointestinal stromal tumour
por: Pulkka, Olli-Pekka, et al.
Publicado: (2017)

Downsizing for cost-effective enterprise computing
Publicado: (1993)

Characterization and assessment of the sensitivity and resistance of a newly established human gastrointestinal stromal tumour xenograft model to treatment with tyrosine kinase inhibitors
por: Van Looy, Thomas, et al.
Publicado: (2014)

Advances in studies of tyrosine kinase inhibitors and their acquired resistance
por: Jiao, Qinlian, et al.
Publicado: (2018)

Early and Next-Generation KIT/PDGFRA Kinase Inhibitors and the Future of Treatment for Advanced Gastrointestinal Stromal Tumor
por: Bauer, Sebastian, et al.
Publicado: (2021)

Effective Downsizing of a Large Oesophageal Gastrointestinal Stromal Tumour with Neoadjuvant Imatinib Enabling an Uncomplicated and without Tumour Rupture Laparoscopic-Assisted Ivor-Lewis Oesophagectomy
por: Neofytou, Kyriakos, et al.
Publicado: (2015)

Clinical efficacy of liver resection after downsizing systemic chemotherapy for initially unresectable liver metastases
por: Kawamura, Junichiro, et al.
Publicado: (2016)

Novel receptor tyrosine kinase targeted combination therapies for imatinib-resistant gastrointestinal stromal tumors (GIST)
por: Mahadevan, Daruka, et al.
Publicado: (2014)

Wide Surgical Margin Improves the Outcome for Patients with Gastrointestinal Stromal Tumors (GISTs)
por: Åhlén, Jan, et al.
Publicado: (2018)

Phase I trial evaluating safety and efficacy of intratumorally administered inflammatory allogeneic dendritic cells (ilixadencel) in advanced gastrointestinal stromal tumors
por: Fröbom, Robin, et al.
Publicado: (2020)

Clinical efficacy of second-generation tyrosine kinase inhibitors in imatinib-resistant gastrointestinal stromal tumors: a meta-analysis of recent clinical trials
por: Wu, Lile, et al.
Publicado: (2014)

Long-term progression-free survival achieved in the skull base metastasis of gastrointestinal stromal tumor with introduction of tyrosine kinase inhibitor: illustrative case
por: Kawanishi, Akiya, et al.
Publicado: (2022)

Neuropsychiatric Adverse Drug Reactions with Tyrosine Kinase Inhibitors in Gastrointestinal Stromal Tumors: An Analysis from the European Spontaneous Adverse Event Reporting System
por: Barbieri, Maria Antonietta, et al.
Publicado: (2023)

Endometrial stromal tumors: immunohistochemical and molecular analysis of potential targets of tyrosine kinase inhibitors
por: Sardinha, Ruth, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_1o6ikqb5sgdpfk3v6eou02q3t4